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Previewstargets for therapy have been reviewed
recently in these pages by Rask-Madsen
and King (2013).
The exciting findings of Nagareddy
et al. mark amajor breakthrough in under-
standing why people with T1D develop
accelerated CAD. This advance also
provides a model that could be used to
address many important unanswered
questions in the field.
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Mechanistic target of rapamycin complex 1 (mTORC1) regulates growth and metabolism by integrating
signals from the cellular environment. Ben-Sahra et al. (2013) and Robitaille et al. (2013) demonstrate a
role for mTORC1 in nucleotide production via S6K1 phosphorylation of CAD, which catalyzes the initial steps
of de novo pyrimidine biosynthesis.Cell growth is an intricately tuned process
involving the coordinated control of
anabolic and catabolic processes. The
mechanistic target of rapamycin complex
1 (mTORC1) lies at the center of this coor-
dination by controlling the production of
macromolecules such as lipids, proteins,
and nucleic acids. Under conditions of
nutrient sufficiency,mTORC1upregulates
protein synthesis by promoting translation
and ribosome biogenesis both directly
and through the 40S ribosomal S6 kinases
(S6K1 and S6K2) and the eukaryotic initia-
tion factor 4E (eIF4E)-binding proteins
(4EBPs) (Ma and Blenis, 2009; Laplante
and Sabatini, 2012). mTORC1 also con-
trols the SREBP1/2 transcription factors,
which drive the expression of numerous
genes involved in lipid/sterol biosynthesis
(Du¨vel et al., 2010). In addition, mTORC1
is believed to control nucleotide syn-thesis, but themechanisms for this regula-
tion have been unclear. Two studies
recently published in Science by Ben-
Sahra et al., (2013) and Robitaille et al.
(2013) demonstrate how mTORC1 pro-
motes de novo pyrimidine synthesis
through posttranslational regulation of
the multifunctional enzyme CAD (carba-
moyl-phosphate synthetase 2, aspartate
transcarbamoylase, dihydroorotase).
Using unbiasedmetabolomics profiling,
Ben-Sahra et al. compared mouse em-
bryonic fibroblasts (MEFs) lacking the
tuberous sclerosis complex 2 (Tsc2) gene
to MEFs with intact Tsc2. Tsc2 is a nega-
tive regulator of mTORC1, and Tsc2 loss
leads to mTORC1 hyperactivation. Of the
20 metabolites that were significantly
increased in the Tsc2/ cells, only
one metabolite, N-carbamoyl-L-aspar-
tate, was decreased in response to bothacute and longer-term treatment with
the mTORC1 inhibitor rapamycin. As
N-carbamoyl-L-aspartate is generated in
the first committed step of de novo pyrim-
idine biosynthesis, the authors focused on
CAD, which catalyzes the first three steps
in this pathway; the E1/E2 enzymatic
activities of CAD catalyze the formation
of N-carbamoyl-L-aspartate, which is
subsequently catalyzed into dihydrooro-
tate by E3 enzymatic activity (Figure 1).
In a different approach, Robitaille et al.
employed phosphoproteomics in MEFs
lacking Raptor, an essential component
of mTORC1, to identify mTORC1 targets.
They identified possible targets involved
in RNA metabolism and DNA replication,
leading to their investigation of CAD.
Both groups identified S1859 on CAD
as an mTORC1-regulated phosphoryla-
tion site via MS/MS. Consistent with them 17, May 7, 2013 ª2013 Elsevier Inc. 633
Figure 1. De Novo Pyrimidine Synthesis Is Regulated by mTORC1 Signaling via S6K1
Phosphorylation of CAD
CAD catalyzes the first three enzymatic steps of de novo pyrimidine biosynthesis by utilizing glutamine,
bicarbonate, and aspartic acid to form a pyrimidine ring that is subsequently attached to ribose, derived
from the pentose phosphate pathway. In addition to the previously described regulation of the pentose
phosphate pathway by mTORC1, Ben-Sahra et al. (2013) and Robitaille et al. (2013) reveal a mode of
regulation of nucleotide biosynthesis by mTORC1 through phosphorylation of CAD by S6K1. This phos-
phorylation promotes specifically the E3 activity of CAD, likely through increased oligomerization of CAD.
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Previewsbasophilic context of S1859, they found
that inhibition or loss of S6K blocks CAD
phosphorylation at S1859. Ben-Sahra
et al. also showed that S6K1 was largely
responsible for the mTORC1-regulated
phosphorylation. To investigate the effect
of S6K phosphorylation on CAD activity,
both groups employed stable-isotope-
labeled 15N-glutamine, which enters into
the first step of de novo pyrimidine syn-
thesis, and measured incorporation into
intermediates of pyrimidine synthesis.
They found growth factor/amino acid-
stimulated increases in incorporation
were inhibited by rapamycin, and Ben-
Sahra et al. also found this incorporation
was dependent on S6K1.634 Cell Metabolism 17, May 7, 2013 ª2013To determine the function of CAD
phosphorylation at S1859, both groups
expressed CAD-WT or CAD-S1859A in
CAD-deficient G9C cells. Ben-Sahra
et al. found that CAD-WT was able to in-
crease incorporation of 15N-glutamine
into downstream metabolites upon insulin
stimulation, whereas CAD-S1859A failed
to stimulate 15N incorporation into any
metabolites downstream of N-carbamoyl-
L-aspartate. Interestingly, CAD-S1859A
was still able to stimulate incorporation of
15N-glutamine into N-carbamoyl-L-aspar-
tate in an insulin/mTORC1-dependent
manner. Since the synthesis of N-carba-
moyl-L-aspartate and dihydroorotate are
catalyzed by the E2 and E3 enzymaticElsevier Inc.activities of CAD, respectively, the authors
propose that phosphorylation of CAD-
S1859 may specifically regulate the activ-
ity of the dihydroorotase (E3) domain
of CAD (see Figure 1). Using another
approach to understandhowS1859phos-
phorylation regulates CAD, Robitaille et al.
performed sedimentation analysis and
observed a subset of CAD-WT that frac-
tionated with a higher molecular size
standard than the bulk of CAD. Because
this was not observed with CAD-S1859A,
the authors propose phosphorylation
at S1859 stimulates formation of a CAD
oligomer, which promotes CAD activity.
In support of this idea, immunohistochem-
istry of CAD revealed an increase in punc-
tate staining upon serum/amino acid stim-
ulation that was blocked by rapamycin.
Robitaille et al. also assayed progres-
sion through the cell cycle and found that
rapamycin caused a delay in S phase pro-
gression that was rescued by adding
uridine to bypass pyrimidine biosynthesis.
Additionally, expression of CAD-WT in
G9C cells promoted proliferation and
colony formation in the absence of uridine,
but CAD-S1859A was less effective.
Pyrimidine synthesis is important for
DNA replication, but cells lacking in
pyrimidines would also have reduced
ribosome biogenesis, and therefore
limited growth with CAD-S1859A is likely
due to a reduction in these and other pro-
cesses. Taken together, the complemen-
tary experiments performedbyBen-Sahra
et al. (2013) and Robitaille et al. (2013)
show that mTORC1/S6K signaling plays
an important role in the regulation of de
novo pyrimidine biosynthesis via CAD
phosphorylation, which contributes to
cell growth and proliferation.
Given the necessity of cancer cells to
generate sufficient nucleotides to meet
the demand for increased DNA replication
and RNA synthesis, and observations that
the mTORC1-S6K pathway is inappropri-
ately activated inmost cancers, the role of
CAD and its regulation in cancer should
be further investigated. Indeed, a previ-
ous study found increased expression of
CAD and a higher rate of pyrimidine
biosynthesis in tumorigenic cells com-
pared to ‘‘normal’’ breast cells (Sigoillot
et al., 2004). In addition, ERK can also
phosphorylate CAD, relieving allosteric
inhibition by UTP and enhancing allosteric
activation by PRPP (Graves et al., 2000).
More work is necessary to understand
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Previewsthe interplay of inputs that regulate CAD
and how their dysregulation may con-
tribute to altered pyrimidine biosynthesis
and cancer.
Another open question is why mTORC1
appears to have more direct control over
the synthesis of pyrimidines than that of
purines. Under the same conditions in
which Robitaille et al. observed a serum-
induced, rapamycin-inhibited increase in
UTP, they saw no rapamycin-dependent
changes in GTP or GDP levels. Synthesis
of both purines and pyrimidines requires
the synthesis of the nitrogenous base and
ribose, derived from the pentose phos-
phate pathway (Figure 1). mTORC1
transcriptionally activates the pentose
phosphate pathway (Du¨vel, et al., 2010),
so mTORC1 can indirectly contribute to
the biosynthesis of both types of nucleo-
tide. However, Ben-Sahra et al. foundthat extended rapamycin treatment was
required to see decreased ribose produc-
tion as compared to the rapid decrease in
pyrimidine production. Thus, in agreement
with Robitaille et al., it appears that
mTORC1 has tighter control over the
synthesis of pyrimidines than purines.
Further work should determine if pyrimi-
dine synthesis indeed plays a greater role
in rapidly growing/dividing cells than
purine synthesis, potentially to equilibrate
levels of pyrimidines and purines for
times of increased DNA synthesis or
ribosome biogenesis. Thus, the studies of
Ben-Sahra et al. and Robitaille et al.
demonstrate a novel role for mTORC1-
activated S6K in regulating pyrimidine
synthesis through the direct phosphor-
ylation-dependent regulation of CAD, a
mechanism that may be exploited to halt
growth of cancers.Cell MetabolisREFERENCES
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Whether the red wine component resveratrol directly activates the NAD+-dependent protein deacetylase
SIRT1 has been debated. A recent study by Hubbard et al. (2013) strengthens the case that SIRT1-activating
compounds (STACs) function as positive allosteric regulators of SIRT1 and thereby regulate mitochondrial
function.A small molecule that effectively delays
the onset of aging-associated diseases,
such as neurodegeneration, diabetes,
and cancer, has the potential to revolu-
tionize modern medicine. One candidate
molecule is resveratrol, an antioxidant
present in red wine discovered to be a
naturally occurring SIRT1 activator. Re-
sveratrol extends life span in yeast,
worms, and flies (Wood et al., 2004) and
improves metabolic parameters in aged
mice and obese humans (Baur et al.,
2006; Timmers et al., 2011). Soon after
the seminal report showing that resvera-
trol activates SIRT1, novel synthetic
SIRT1 activators were identified and
further developed to reduce off-target
effects and improve their pharmacoki-netic properties. However, a number of
controversies arose regarding themecha-
nism of action of resveratrol and synthetic
SIRT1-activating compounds (STACs). Of
significant concern was the demon-
stration that STACs and resveratrol
enhanced SIRT1 deacetylase activity
toward peptide substrates covalently
bound to a fluorophore but not toward
native peptide substrates (Pacholec
et al., 2010). This discrepancy raised sig-
nificant questions on the validity of re-
sveratrol and STACs as direct SIRT1
activators in vivo. However, subsequent
studies showed that STAC treatment
offered remarkable protective benefits
against cardiovascular andmetabolic dis-
ease as well as locomotor dysfunction inaged mice, revealing some discrepancy
between the in vitro and in vivo effects
(Baur et al., 2012).
To address this controversy, Sinclair
and his team (who published the original
resveratrol/SIRT1 story [Howitz et al.,
2003]), set out to re-evaluate their previ-
ous findings by testing a clever alternative
hypothesis. Could the failure of STACs to
deacetylate native, nontagged peptides
in vitro be explained by a requirement for
the structure mimicked by the fluorophore
tag? In other words, was the bulky, hydro-
phobic fluorophore mimicking properties
of endogenous substrates required for
SIRT1 activation by STACs? Two inde-
pendent assays, one enzymatic and the
other mass-spectrometry based, werem 17, May 7, 2013 ª2013 Elsevier Inc. 635
